Amplio Pharma Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series A
  • (Upcoming)

  • Latest Deal Amount
  • $11.5M

  • Investors
  • 8

Amplio Pharma General Information

Description

Developer of improved versions of existing drugs designed to improve the treatment of rheumatoid arthritis. The company develops a methotrexate-based product that uses proprietary retention technology to increase the amount of methotrexate retained inside immune cells, enabling healthcare professionals to improve patient response rates.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Hulstweg 11
  • 1032 LB Amsterdam
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • Hulstweg 11
  • 1032 LB Amsterdam
  • Netherlands

Amplio Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amplio Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) $11.5M Upcoming Clinical Trials - Phase 1
6. Later Stage VC 17-Feb-2026 Completed Clinical Trials - Phase 1
5. Seed Round 04-Apr-2025 Completed Clinical Trials - Phase 1
4. Seed Round 11-Mar-2025 Completed Clinical Trials - Phase 1
3. Seed Round 28-Sep-2023 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view Amplio Pharma’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Amplio Pharma Patents

Amplio Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3630188-A1 A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy Active 31-May-2017
EP-3630188-B1 A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy Active 31-May-2017
US-20200101074-A1 A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy Active 31-May-2017
ES-2897200-T3 A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of the composition in therapy Active 31-May-2017
US-11883405-B2 Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy Active 31-May-2017 A61K31/519
To view Amplio Pharma’s complete patent history, request access »

Amplio Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amplio Pharma Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amsterdam UMC Ventures Holding Venture Capital Minority
ROM InWest Asset Manager Minority
UvA Ventures Holding Venture Capital Minority
Innovatiefonds Noord-Holland Venture Capital Minority
Libertatis Ergo Holding (LEH) Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Amplio Pharma FAQs

  • When was Amplio Pharma founded?

    Amplio Pharma was founded in 2020.

  • Where is Amplio Pharma headquartered?

    Amplio Pharma is headquartered in Amsterdam, Netherlands.

  • What is the size of Amplio Pharma?

    Amplio Pharma has 9 total employees.

  • What industry is Amplio Pharma in?

    Amplio Pharma’s primary industry is Drug Discovery.

  • Is Amplio Pharma a private or public company?

    Amplio Pharma is a Private company.

  • What is Amplio Pharma’s current revenue?

    The current revenue for Amplio Pharma is .

  • How much funding has Amplio Pharma raised over time?

    Amplio Pharma has raised $2.19M.

  • Who are Amplio Pharma’s investors?

    Amsterdam UMC Ventures Holding, ROM InWest, UvA Ventures Holding, Innovatiefonds Noord-Holland, and Libertatis Ergo Holding (LEH) are 5 of 8 investors who have invested in Amplio Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process